Advertisement

Advertisement

HK:1652 Stock Latest News

Fusen Pharmaceutical Wins China Approval for New Lornoxicam Injection

Company AnnouncementsFusen Pharmaceutical Wins China Approval for New Lornoxicam Injection

Fusen Pharmaceutical Sets 2026 AGM to Renew Board, Auditor and Share Issuance Mandate

PremiumCompany Announcements

Fusen Pharmaceutical Sets 2026 AGM to Renew Board, Auditor and Share Issuance Mandate

21d ago

Fusen Pharma Wins Mainland China Approval for New Dydrogesterone Tablet

PremiumCompany Announcements

Fusen Pharma Wins Mainland China Approval for New Dydrogesterone Tablet

23d ago

Fusen Pharmaceutical Wins China Approval for Glucosamine Osteoarthritis Capsule

PremiumCompany Announcements

Fusen Pharmaceutical Wins China Approval for Glucosamine Osteoarthritis Capsule

1M ago

Fusen Pharmaceutical Switches Auditor After Dispute Over 2025 Audit Fee

PremiumCompany Announcements

Fusen Pharmaceutical Switches Auditor After Dispute Over 2025 Audit Fee

1M ago

Fusen Pharmaceutical Narrows Annual Loss Despite Revenue Decline

PremiumCompany AnnouncementsFusen Pharmaceutical Narrows Annual Loss Despite Revenue Decline

2M ago

Fusen Pharmaceutical Sets March 2026 Board Meeting to Approve 2025 Results

Company Announcements

Fusen Pharmaceutical Sets March 2026 Board Meeting to Approve 2025 Results

2M ago

Fusen Pharmaceutical Wins China Approval for New Phosphate Injection

Company Announcements

Fusen Pharmaceutical Wins China Approval for New Phosphate Injection

5M ago

Fusen Pharmaceutical Replaces KPMG With CCTH as Auditor to Cut Costs

PremiumCompany Announcements

Fusen Pharmaceutical Replaces KPMG With CCTH as Auditor to Cut Costs

5M ago

Fusen Pharmaceutical Gains Approval for Nicardipine Hydrochloride Injection

PremiumCompany Announcements

Fusen Pharmaceutical Gains Approval for Nicardipine Hydrochloride Injection

5M ago

Fusen Pharmaceutical’s New Hypertension Drug Gains Approval in China

PremiumCompany Announcements

Fusen Pharmaceutical’s New Hypertension Drug Gains Approval in China

6M ago

Fusen Pharmaceutical’s Enzalutamide Soft Capsule Approved for Prostate Cancer Treatment in China

PremiumCompany Announcements

Fusen Pharmaceutical’s Enzalutamide Soft Capsule Approved for Prostate Cancer Treatment in China

7M ago

Fusen Pharmaceutical’s Product Selected in National Procurement

PremiumCompany AnnouncementsFusen Pharmaceutical’s Product Selected in National Procurement

7M ago

Fusen Pharmaceutical Announces Disposal of Equity Interests

Company Announcements

Fusen Pharmaceutical Announces Disposal of Equity Interests

7M ago

Fusen Pharmaceutical Announces Board Composition and Committee Roles

Company Announcements

Fusen Pharmaceutical Announces Board Composition and Committee Roles

8M ago

Fusen Pharmaceutical Announces Board Restructuring

PremiumCompany Announcements

Fusen Pharmaceutical Announces Board Restructuring

8M ago

Fusen Pharmaceutical Announces Strategic Disposal of Subsidiary

PremiumCompany Announcements

Fusen Pharmaceutical Announces Strategic Disposal of Subsidiary

8M ago

Fusen Pharmaceutical Gains Approval for New Diabetes Treatment

PremiumCompany Announcements

Fusen Pharmaceutical Gains Approval for New Diabetes Treatment

8M ago

Fusen Pharmaceutical Reports Significant Revenue Decline in H1 2025

PremiumCompany Announcements

Fusen Pharmaceutical Reports Significant Revenue Decline in H1 2025

9M ago

Fusen Pharmaceutical Schedules Board Meeting to Review Interim Results

PremiumCompany AnnouncementsFusen Pharmaceutical Schedules Board Meeting to Review Interim Results

9M ago

Fusen Pharmaceutical Reports Unanimous Approval of AGM Resolutions

Company Announcements

Fusen Pharmaceutical Reports Unanimous Approval of AGM Resolutions

12M ago

Fusen Pharmaceutical Announces Change in Shareholding Structure

Company Announcements

Fusen Pharmaceutical Announces Change in Shareholding Structure

12M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >